本報告已在2011年07月19日停止出版。
高通量藥物篩選（High Throughput Screening - HTS）技術，能夠將與目標分子作用的低分子化合物迅速篩選出來，因此能夠縮短製藥過程，提升成本效率，增加獲利。
專精高科技領域諮詢市調的美國專業公司 Frost & Sullivan (總公司: 德州)，調查分析了歐洲高通量藥物篩選技術市場後，出版了一本綜合報告書 "Strategic Analysis of the European High Throughput Screening (HTS) Market"。
報告書內容包括：歐洲各地區 / 部門市場收益分析、各地區主要發展與障礙因素、影響市場的技術革新探討等等，內容綱要摘記如下：
1.概觀
2.調查對象與方法
3.簡介與背景
4.市場動態
- 1. 主要市場動態
- 2. 市場發展因素
- 3. 市場障礙因素
- 4. 業界課題
- 5. 主要技術趨勢
- 6. 技術發展因素
- 7. 技術障礙因素
5.整體市場預測
- 1. 預測
- 2. 整體收益預測
- 3. 收益分析
- 4. 市場計畫評估指標
- 5. 各地區收益趨勢
- 6. 藥物研發總成本
- 7. 各地區製藥市場比率
- 8. 企業資訊
6.策略分析與建議
- 1. 市場成熟過程
- 2. 策略性洞察
- 3. 潛在威脅
- 4. 競爭架構
- 5. 市場可能性
- 6. 三階段策略
- 7. 定價策略
- 8. 未來預測
- 9. 解決問題
7.Frost & Sullivan Awards
8.市場業者
9.決策支援資料庫
10.Frost & Sullivan介紹
Research Overview
High Throughput Drug Screening - Allaying Risks Associated with Drug
Discovery
The development of effective drugs remains a challenging, risky and expensive
endeavour. High throughput drug screening (HTS) is emerging as a saviour in the
field of drug discovery as pharmaceuticals and biotechnology companies compete
to become the first to market new drugs. By shortening the drug discovery cycle,
HTS offers the opportunity to capture the maximum market share and optimise
revenue generation within the first year of entry. HTS also increases the
chances of clearing clinical trials by addressing issues related to
pharmacokinetics, animal toxicity and side effects. In spite of high equipment
costs and poor quality of lead compounds presenting a significant challenge, HTS
has the potential to yield both mechanistic insights and new drug leads with
unparalleled efficiency through investment and innovation.
This Frost & Sullivan research evaluates the key drivers and challenges
in the European HTS market. It also examines the important technology trends and
provides strategic recommendations for designing high-impact action plans.
Outsourcing HTS to Custom Screeners Proving Extremely Cost-effective
Outsourcing HTS has emerged as a cost-effective option for multinational
pharmaceuticals and biotechnology companies that are under pressure to discover
and develop new therapeutics at lesser costs and within shorter time frames.
Research indicates that approximately 10 per cent of the funds allocated to
early stage discovery are accounted for by outsourcing. "Outsourcing not
only compresses the time line for drug development and reduces the overall
costs, it also provides access to additional drug entities and innovative
technology," explains the analyst of this research.
Market for HTS is Expanding
The HTS field continues to be highly dynamic and competitive.
"Information sharing between competing companies, coupled with open
technology transfer meetings and publications, has greatly accelerated the
development of the HTS industry," says the analyst. The success of genomic
and proteomic searches provides a more comprehensive list of cellular targets.
The anticipated use of functional genomics and proteomics to bridge the gap
between physical-chemical activities and the drug development process is also
expected to be a major driver in the HTS market.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) programme that
provides established and emerging firms with powerful growth visions. Moving
beyond token mission statements, GPS provides an actionable vision to growth
consulting partners by illustrating how key intelligence and strategic research
based on defined goals can guide day-to-day behaviour and overall company
direction. The foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximise the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programmes that deliver improved market success. Frost &
Sullivans strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clients growth.
1 STRATEGIC ANALYSIS OF THE EUROPEAN HIGH THROUGHPUT SCREENING MARKET
- Overview
- Research Scope & Methodology
- Research Scope & Methodology
- Introduction & Background
- Introduction & Background
- Market Dynamics
- Key Market Trends
- Market Drivers
- Market Restraints
- Industry Challenges
- Key Technology Trends
- Technology Drivers
- Technology Restraints
- Total Market Forecasts
- Assumptions
- Total Revenue Forecasts
- Revenue Analysis
- Key Market Engineering Measurements
- Revenue Trends By Geographical Region
- Total Drug Development Expenditure
- Drug Discovery Market Share By Geographical Region
- Company Profiles
- Strategic Analysis & Recommendations
- Market Maturation Process
- Strategic Anticipation
- Potential Threats
- Competitive Framework
- Market Potential
- Three Levels Of Strategies
- Pricing Strategy
- What Can Be Expected in the Future?
- Meeting the Challenge
- Frost & Sullivan Awards
- Frost & Sullivan Awards
- Competitive Strategy Leadership Award
- Customer Service Innovation Award
- Market Leadership Award
- Technology Innovation Award
- Growth Strategy Leadership Award
- Industry Participants
- Decision Support Databases
- Decision Support Databases
- Frost & Sullivan
- Healthcare Team
- Our Capabilities
